Berotralstat Synthesis and Manufacturing
The patent application WO2015134998, filed by BPS Holding, Inc., describes methods for synthesizing berotralstat, a drug used to prevent hereditary angioedema (HAE) attacks [1]. The synthesis involves several key chemical transformations to construct the complex molecule.
What are the steps in the WO2015134998 berotralstat synthesis?
The patent details a convergent synthesis approach. A core intermediate, referred to as "compound 100," is prepared through a series of reactions, including protection of functional groups and cyclization steps. This intermediate is then coupled with another key fragment, "compound 200," which is also synthesized through multi-step processes involving amidation and other functional group manipulations. The final step typically involves deprotection to yield berotralstat [1]. Specific examples within the patent illustrate the reaction conditions, reagents, and purification methods used at each stage.
How does this synthesis differ from earlier methods?
While WO2015134998 focuses on efficient and scalable manufacturing, earlier synthetic routes may have prioritized proof-of-concept or laboratory-scale preparation. The methods described in this patent aim to optimize yields, reduce the number of steps, and improve the purity of the final product, making it suitable for commercial production [1]. For example, the patent describes specific crystallization techniques to obtain berotralstat in a desired polymorphic form [1].
What is the chemical structure of berotralstat?
Berotralstat, with the chemical name N-(4-((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-((methoxycarbonyl)amino)cyclohexyl)phenyl)-3-(1H-pyrazol-1-yl)benzamide, is a complex organic molecule [1]. Its structure features a central cyclohexyl ring with specific stereochemistry, substituted with protected amino groups. This ring system is linked to a phenyl ring, which in turn is attached to a benzamide moiety containing a pyrazole substituent.
What are the manufacturing challenges for berotralstat?
The synthesis of berotralstat presents several manufacturing challenges due to its complex structure and stereochemical requirements. These include:
* Stereocontrol: Ensuring the correct three-dimensional arrangement of atoms at specific chiral centers is critical for drug efficacy and safety [1].
* Purity: Achieving high purity levels requires effective separation of impurities and byproducts formed during the synthesis [1].
* Scalability: Transitioning from laboratory-scale synthesis to large-scale manufacturing requires robust and reproducible processes that can be performed safely and economically [1].
* Polymorphism: Controlling the solid-state form (polymorph) of the drug substance is important for its physical properties, such as solubility and stability [1].
When does berotralstat's patent exclusivity expire?
Information regarding the specific patent expiry dates for berotralstat is available through specialized databases. DrugPatentWatch.com tracks patent filings and expiry dates for pharmaceuticals.
Who developed berotralstat?
Berotralstat was developed by BPS Holding, Inc., which is now part of BioCryst Pharmaceuticals, Inc. [1].